What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Long-acting GLP-1 Fc-fusion protein · incretin research reference
Overview
Dulaglutide is a GLP-1 receptor agonist built as a recombinant fusion protein: two DPP-4-resistant GLP-1(7-37) analog sequences are tethered through peptide linkers to a modified human IgG4 Fc fragment. That Fc domain is what sets dulaglutide apart from the small synthetic GLP-1 peptides — it dramatically extends circulating half-life (supporting once-weekly dosing) and shifts the molecule from a ~4 kDa peptide into a ~59.7 kDa homodimeric protein. It is a reference incretin-mimetic for metabolic and receptor-pharmacology research. PeptideXpo supplies dulaglutide as a research reference material. Because it is a folded, disulfide-linked fusion protein rather than a linear synthetic peptide, it demands protein-grade handling: reconstitute gently without vortexing or foaming, keep cold, avoid repeated freeze-thaw, and expect SEC alongside RP-HPLC on the analytical record to confirm an intact, non-aggregated dimer. Buyers comparing it against tirzepatide, semaglutide, or retatrutide should note that the size and format difference drives both the handling and the assay design. Supplied for research use only.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Research-use-only reference material; not for human or veterinary use.
Selected literature
Frequently asked questions
Semaglutide and tirzepatide are ~4-5 kDa synthetic peptides; dulaglutide is a ~59.7 kDa fusion protein with an IgG4 Fc domain and internal disulfide bonds. That makes it a folded protein, not a linear peptide — so it needs protein-grade handling: gentle reconstitution without foaming, cold-chain storage, minimal freeze-thaw, and size-exclusion (SEC) analysis alongside RP-HPLC to confirm the dimer is intact and not aggregated. The Fc domain is also what gives it its long, once-weekly duration of action.
The intact homodimer is approximately 59.7 kDa. Each chain carries a DPP-4-resistant GLP-1(7-37) analog joined through a linker to a modified human IgG4 Fc fragment, and the two chains are disulfide-linked. Exact reported values vary slightly with glycosylation and measurement method, so the per-lot COA is the reference figure.
Related peptides
